Treatment for Mild Cognitive Impairment (MCI)
This study is evaluating whether a new treatment approach called COT might help protect the memory and brain regions of people who are already showing signs of memory loss.
See full descriptionAbout the trial for Mild Cognitive Impairment (MCI)
Treatment Groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 65 and older. There are 6 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Treatment will improve 5 primary outcomes and 9 secondary outcomes in patients with Mild Cognitive Impairment (MCI). Measurement will happen over the course of Baseline and 9 months.
Patient Q & A Section
What is mild cognitive impairment (mci)?
In a clinical practice, many of the most common reasons for testing an adult suspected of a primary brain disorder are in fact not pathological but are a consequence of other medical and psychiatric problems. The present investigation indicates that a history of mci (including subjective and objective complaints and psychophysiological disturbances) in these adults is frequently, but not universally, associated with objective and subjective memory deficits.
What are common treatments for mild cognitive impairment (mci)?
Most MCI patients receive preventive medical treatment and counselling. A small number receive cognitive remediation therapy (CRT), particularly in the domains of episodic memory, verbal learning, and processing speed. It is generally used for individuals with MCI who experience persistent, moderate, and severe impairments in the individual's cognitive abilities. While its use is widespread, there is significant controversy over whether or not CRT is effective for modifying cognition in patients with MCI.
What are the signs of mild cognitive impairment (mci)?
In this pilot study of healthy older adults, a number of the signs that clinicians can expect in patients with mci differed from those that have been reported in the clinical research literature. Findings from a recent study will guide the evaluation of the symptoms of mci in the older adult.
How many people get mild cognitive impairment (mci) a year in the United States?
We estimate that an average of 6% of the adult population (aged >55 years) has [mild cognitive impairment] (mci). This is an additional 4 million people with undiagnosed MCI and an additional 2 million people with MCI untreated. MCI prevalence is also more common in females than in males. Additional work will be needed to determine whether or not screening for MCI may improve patient outcomes and reduce healthcare costs for persons with MCI.
Can mild cognitive impairment (mci) be cured?
When a person with mci is prescribed the appropriate medication and has appropriate adherence to the treatment, the chances of experiencing a positive outcome and not experiencing an adverse event are quite high.
What causes mild cognitive impairment (mci)?
Many factors may contribute to mci, including genetic vulnerability, age, and environmental factors such as smoking and air pollution. Some evidence also suggests that the condition may be more common in those who report poorer health, and may be more common than previously thought. There is ongoing work to assess the effect of diet and some medications in Mci.\n
What is the primary cause of mild cognitive impairment (mci)?
In this cohort, the most common causes of [mci]] are Alzheimer's disease (AD) and [depression] whereas amyloid plaque formation and tangle formation are associated with memory decline. However, these common diagnoses may not tell us much about the individual-level pathology in patients with mci.
What does treatment usually treat?
While cognitive impairment is commonplace, most of the people with mild cognitive impairment (mci) report they do not need treatment. However, there is no clear information regarding treatment preferences, effectiveness, and adherence among patients with mci. Therefore, further studies need to be done across countries to further determine the needs and preferences of patients with mci.
What is treatment?
Currently, there is no clear recommendation for treatments for MCI, because of the lack of information on the treatment of MCI and the number of treatments, the variety of MCI, and the differing conceptualizations of MCI, which has made it difficult to set definitive treatment guidelines. The consensus is that MCI can persist for many years and can occur in a variety of brain disorders. Given the heterogeneity of MCI, it is not expected that an exact definition of treatment can be determined; however research is still ongoing. There is a need for a deeper understanding of treatment options through longitudinal studies.
Have there been any new discoveries for treating mild cognitive impairment (mci)?
Researchers should not consider MCI to be an end-stage illness of the brain. New research should focus on how to maintain the brain's ability to function. This might include cognitive, behavioral, and physiological components for healthy aging and mci.
Does treatment improve quality of life for those with mild cognitive impairment (mci)?
Treatment for those in receipt of CCRT was not associated with an increase in QOL. On the contrary, some QOL scores actually declined for those in receipt of CCRT.
What are the common side effects of treatment?
Treatment affected the patients in different ways; some adverse events could only manifest themselves after the conclusion of treatment whereas others only appeared upon completion of the treatment. In some cases, multiple medications were associated with new side effects. Data from a recent study are mostly related to age, sex, underlying disease and treatment used. The prevalence of most of the adverse effects appears to be comparatively low to other patients using different medication classes undergoing similar therapies. There is a lack of conclusive evidence for serious side effects and the existence of safe treatments with which to treat patients with mCI.